Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance.
Pósa V, Stefanelli A, Nunes JHB, Hager S, Mathuber M, May NV, Berger W, Keppler BK, Kowol CR, Enyedy ÉA, Heffeter P.
Pósa V, et al.
Cancers (Basel). 2022 Sep 14;14(18):4455. doi: 10.3390/cancers14184455.
Cancers (Basel). 2022.
PMID: 36139615
Free PMC article.
COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thiosemicarbazone, this compound contains an N,N,S-chelating moiety and is, therefore, expected to bind endogenous metal ions. ...
COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thio …